NL8701254A - Werkwijze voor het bereiden van conjugaten van metalloproteinen en nieuwe derivaten daarvan. - Google Patents

Werkwijze voor het bereiden van conjugaten van metalloproteinen en nieuwe derivaten daarvan. Download PDF

Info

Publication number: NL8701254A
Authority: NL; Netherlands
Prior art keywords: gly; val; ala; asp; ser
Prior art date: 1986-06-02

Application number

NL8701254A

Other languages

English (en)

Dutch (nl)

Original Assignee

Debiopharm Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-06-02

Filing date

1987-05-26

Publication date

1988-01-04

1987-05-26 Application filed by Debiopharm Sa filed Critical Debiopharm Sa

1988-01-04 Publication of NL8701254A publication Critical patent/NL8701254A/nl

Links

102000010750 Metalloproteins Human genes 0.000 title claims description 21
108010063312 Metalloproteins Proteins 0.000 title claims description 21
238000004519 manufacturing process Methods 0.000 title description 2
239000002184 metal Substances 0.000 claims description 14
229910052751 metal Inorganic materials 0.000 claims description 14
238000000034 method Methods 0.000 claims description 12
150000002739 metals Chemical class 0.000 claims description 10
102000008100 Human Serum Albumin Human genes 0.000 claims description 9
239000004971 Cross linker Substances 0.000 claims description 8
239000012634 fragment Substances 0.000 claims description 8
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 7
108091006905 Human Serum Albumin Proteins 0.000 claims description 7
230000004071 biological effect Effects 0.000 claims description 7
108090000765 processed proteins & peptides Proteins 0.000 claims description 7
229910052725 zinc Inorganic materials 0.000 claims description 7
102000003505 Myosin Human genes 0.000 claims description 6
108060008487 Myosin Proteins 0.000 claims description 6
229910052802 copper Inorganic materials 0.000 claims description 6
229940127121 immunoconjugate Drugs 0.000 claims description 6
102000004169 proteins and genes Human genes 0.000 claims description 5
108090000623 proteins and genes Proteins 0.000 claims description 5
239000000427 antigen Substances 0.000 claims description 4
102000036639 antigens Human genes 0.000 claims description 4
108091007433 antigens Proteins 0.000 claims description 4
238000004132 cross linking Methods 0.000 claims description 3
150000001718 carbodiimides Chemical class 0.000 claims description 2
MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 claims description 2
102000004196 processed proteins & peptides Human genes 0.000 claims description 2
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 3
101000693913 Homo sapiens Albumin Proteins 0.000 claims 2
102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
150000001413 amino acids Chemical group 0.000 claims 2
239000000178 monomer Substances 0.000 claims 2
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic anhydride Substances CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims 1
150000002463 imidates Chemical class 0.000 claims 1
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
102000006410 Apoproteins Human genes 0.000 description 8
108010083590 Apoproteins Proteins 0.000 description 8
239000011701 zinc Substances 0.000 description 8
102000009027 Albumins Human genes 0.000 description 7
108010088751 Albumins Proteins 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
239000010949 copper Substances 0.000 description 6
238000000502 dialysis Methods 0.000 description 6
239000004471 Glycine Substances 0.000 description 5
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 5
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
239000000539 dimer Substances 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
102000019197 Superoxide Dismutase Human genes 0.000 description 3
108010012715 Superoxide dismutase Proteins 0.000 description 3
238000000746 purification Methods 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000007858 starting material Substances 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
102000014914 Carrier Proteins Human genes 0.000 description 2
108010078791 Carrier Proteins Proteins 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
229920005654 Sephadex Polymers 0.000 description 2
239000012507 Sephadex™ Substances 0.000 description 2
239000002738 chelating agent Substances 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000002523 gelfiltration Methods 0.000 description 2
230000002779 inactivation Effects 0.000 description 2
239000000203 mixture Substances 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
239000000047 product Substances 0.000 description 2
239000012064 sodium phosphate buffer Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000008685 targeting Effects 0.000 description 2
238000000108 ultra-filtration Methods 0.000 description 2
FMJUDUJLTNVWCH-UHFFFAOYSA-N 2-ethoxy-3-(4-hydroxyphenyl)propanoic acid Chemical compound CCOC(C(O)=O)CC1=CC=C(O)C=C1 FMJUDUJLTNVWCH-UHFFFAOYSA-N 0.000 description 1
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
229910017518 Cu Zn Inorganic materials 0.000 description 1
229910017752 Cu-Zn Inorganic materials 0.000 description 1
-1 Cu-Zn peroxide Chemical class 0.000 description 1
229910017943 Cu—Zn Inorganic materials 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
102000005385 Intramolecular Transferases Human genes 0.000 description 1
108010031311 Intramolecular Transferases Proteins 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
230000004075 alteration Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
229940045799 anthracyclines and related substance Drugs 0.000 description 1
230000006793 arrhythmia Effects 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
230000008901 benefit Effects 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229910017052 cobalt Inorganic materials 0.000 description 1
239000010941 cobalt Substances 0.000 description 1
GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
TVZPLCNGKSPOJA-UHFFFAOYSA-N copper zinc Chemical compound [Cu].[Zn] TVZPLCNGKSPOJA-UHFFFAOYSA-N 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000002270 exclusion chromatography Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
230000003993 interaction Effects 0.000 description 1
239000002808 molecular sieve Substances 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
FIKAKWIAUPDISJ-UHFFFAOYSA-L paraquat dichloride Chemical compound [Cl-].[Cl-].C1=C[N+](C)=CC=C1C1=CC=[N+](C)C=C1 FIKAKWIAUPDISJ-UHFFFAOYSA-L 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
231100000572 poisoning Toxicity 0.000 description 1
230000000607 poisoning effect Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
238000010791 quenching Methods 0.000 description 1
230000000171 quenching effect Effects 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
241000894007 species Species 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
229940032362 superoxide dismutase Drugs 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Analytical Chemistry (AREA)
Toxicology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

NL8701254A 1986-06-02 1987-05-26 Werkwijze voor het bereiden van conjugaten van metalloproteinen en nieuwe derivaten daarvan. NL8701254A (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB8613315A GB2191200B (en)	1986-06-02	1986-06-02	Process for preparing conjugates of metalloproteins and novel derivatives thereof
GB8613315		1986-06-02

Publications (1)

Publication Number	Publication Date
NL8701254A true NL8701254A (nl)	1988-01-04

Family

ID=10598769

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL8701254A NL8701254A (nl)	1986-06-02	1987-05-26	Werkwijze voor het bereiden van conjugaten van metalloproteinen en nieuwe derivaten daarvan.

Country Status (10)

Country	Link
JP (1)	JPS62292800A (da)
BE (1)	BE1002130A3 (da)
CH (1)	CH674939A5 (da)
DE (1)	DE3718476A1 (da)
DK (1)	DK280187A (da)
ES (1)	ES2004734A6 (da)
FR (1)	FR2603287B1 (da)
GB (1)	GB2191200B (da)
IT (1)	IT1207805B (da)
NL (1)	NL8701254A (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1317895B1 (it) *	2000-08-10	2003-07-15	Univ Napoli Federico Ii	Pseudo-metalloproteine, loro preparazione e loro uso.
MX354530B (es) *	2013-02-27	2018-02-19	Univ Autonoma Del Estado De Morelos	Composiciones que comprenden immp para coadyuvar al desarrollo, crecimiento y mejora de los parámetros productivos de animales de interés zootécnico, y uso de las mismas.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1168150A (en) *	1981-12-18	1984-05-29	The Governors Of The University Of Alberta	Targeting conjugates of albumin and therapeutic agents

1986
- 1986-06-02 GB GB8613315A patent/GB2191200B/en not_active Expired - Fee Related
1987
- 1987-05-25 CH CH2040/87A patent/CH674939A5/fr not_active IP Right Cessation
- 1987-05-26 NL NL8701254A patent/NL8701254A/nl not_active Application Discontinuation
- 1987-05-29 ES ES8701587A patent/ES2004734A6/es not_active Expired
- 1987-05-29 JP JP62137600A patent/JPS62292800A/ja active Pending
- 1987-06-01 IT IT8705187A patent/IT1207805B/it active
- 1987-06-01 FR FR878707639A patent/FR2603287B1/fr not_active Expired - Fee Related
- 1987-06-01 DK DK280187A patent/DK280187A/da not_active Application Discontinuation
- 1987-06-01 BE BE8700605A patent/BE1002130A3/fr not_active IP Right Cessation
- 1987-06-02 DE DE19873718476 patent/DE3718476A1/de not_active Withdrawn

Also Published As

Publication number	Publication date
GB2191200A (en)	1987-12-09
DK280187D0 (da)	1987-06-01
IT1207805B (it)	1989-06-01
BE1002130A3 (fr)	1990-07-24
IT8705187A0 (it)	1987-06-01
DE3718476A1 (de)	1987-12-03
DK280187A (da)	1987-12-03
JPS62292800A (ja)	1987-12-19
FR2603287A1 (fr)	1988-03-04
FR2603287B1 (fr)	1991-02-08
GB8613315D0 (en)	1986-07-09
GB2191200B (en)	1990-07-11
CH674939A5 (da)	1990-08-15
ES2004734A6 (es)	1989-02-01

Legal Events

Date	Code	Title	Description
1993-01-04	BV	The patent application has lapsed

Publication	Publication Date	Title
JP3497175B2 (ja)	2004-02-16	一価の（ｍｏｎｏｖａｌｅｎｔ）抗体フラグメント
KR900004801B1 (ko)	1990-07-06	중합체 접합된 단백질, 상기 단백질이 용해되어 있는 약제학적 조성물 및 상기 조성물의 제조방법
CA2288994C (en)	2011-07-05	Polyalkylene oxide-modified single chain polypeptides
JP3280376B2 (ja)	2002-05-13	多価抗原結合性蛋白質
JP4456758B2 (ja)	2010-04-28	二価抗体フラグメント
EP0510949B2 (en)	2003-04-02	Cytomodulating conjugates of members of specific binding pairs
KR0152272B1 (ko)	1998-10-15	암 진단 및 치료용 면역접합체
US4350626A (en)	1982-09-21	Antitumor hybrid and process for the preparation thereof
JPH03503759A (ja)	1991-08-22	ポリマーとコロニー刺激因子‐１との接合体
JP2907474B2 (ja)	1999-06-21	共有結合で連結した２つ以上のＦｃ領域を有する抗体複合体
NO872227L (no)	1987-11-30	Tumornekrosefaktorformulering.
JP2009523743A (ja)	2009-06-25	癌治療のための医薬品およびその使用
Tan et al.	1998	Engineering the isoelectric point of a renal cell carcinoma targeting antibody greatly enhances scFv solubility
WO1991019515A1 (en)	1991-12-26	Oligomeric immunoglobulin constant domain mutant with enhanced complement-mediated cytolytic activity
JPH0259128B2 (da)	1990-12-11
EA012507B1 (ru)	2009-10-30	Высокоаффинные мелан-а т-клеточные рецепторы
NL8701254A (nl)	1988-01-04	Werkwijze voor het bereiden van conjugaten van metalloproteinen en nieuwe derivaten daarvan.
Kojima et al.	1993	Conjugation of copper-zinc superoxide dismutase with succinylated gelatin: Pharmacological activity and cell-lubricating function
Mital	2004	Polysialic acids: A tool for the optimisation of peptide and protein therapeutics
Veronese et al.	1992	Preparation and properties of monomethoxypoly (ethylene glycol)-modified enzymes for therapeutic applications
Ahmad et al.	1988	Strategies for designing antibody-toxin conjugates
JPS5942323A (ja)	1984-03-08	選択的殺細胞性蛋白複合体及びその製造方法
KR20240102886A (ko)	2024-07-03	면역 활성 인터루킨 2 아날로그 결합체를 포함하는 제제
WO1994002174A1 (fr)	1994-02-03	Immunocomplexe
Odajima et al.	1998	A chemical modification of myeloperoxidase and lactoperoxidase with 2‐(O‐methoxypolyethylene glycol)‐4, 6‐dichloro‐s‐triazine (activated PEG1)